Pyroptosis: A New Strategy for Oncolytic Virus Therapy of Cancer
DOI:
https://doi.org/10.61173/nv67xd82Keywords:
-oncolytic virus, immunotherapy, pyroptosis, tumor microenvironment, gasderminAbstract
In recent years, pyroptosis, as a form of proinflammatory programmed death, has been found to play a key role in the anti-tumor mechanism of OVs. This article systematically reviews the molecular mechanism of pyroptosis and tumor immune regulation, summarizes novel therapeutic strategies such as genetic engineering of OVs to enhance pyroptosis and combined with immune checkpoint inhibitors (ICIs), and analyzes their effects on tumor microenvironment (TME) immune remodeling. The results showed that OVs mainly induced pyroptosis by activating the caspase-3/GSDME pathway, releasing inflammatory factors (such as IL-18, HMGB1) and damage-associated molecular patterns (DAMPs), recruiting CD8+ T cells and natural killer (NK) cell infiltration, and thus transforming "cold tumors" into "hot tumors". OVs can be transformed to express GSDM proteins, regulate mitochondrial dysfunction, and target tumor immune components to promote the treatment of tumors through pyroptosis. This article provides a theoretical basis for the clinical transformation of OVs and suggests that pyroptosis-based combination therapy may become an important direction for future tumor im-munotherapy.
References
[1] Z. Rao, Y. Zhu, P. Yang, Z. Chen, Y. Xia, C. Qiao, W. Liu, H. Deng, J. Li, P. Ning, and Z. Wang, “Pyroptosis in inflammatory diseases and cancer,” Theranostics, vol. 12, no. 9, pp. 4310– 4329, May 2022.
[2] Y. Wang, B. Yin, D. Li, G. Wang, X. Han, and X. Sun, “GSDME mediates caspase-3-dependent pyroptosis in gastric cancer,” Biochem. Biophys. Res. Commun., vol. 495, pp. 1418– 1425, 2018.
[3] J. Hou, J. M. Hsu, and M. C. Hung, “Molecular mechanisms and functions of pyroptosis in inflammation and antitumor immunity,” Mol. Cell, vol. 81, no. 22, pp. 4579–4590, Nov. 2021.
[4] T. Du, J. Gao, P. Li, Y. Wang, Q. Qi, and X. Liu et al., “Pyroptosis, metabolism, and tumor immune microenvironment,” Clin. Transl. Med., vol. 11, e492, 2021.
[5] X. Y. Chen, Y. Liu, W. B. Zhu, S. H. Li, S. Wei, J. Cai, Y. Lin, J. K. Liang, G. M. Yan, L. Guo, and C. Hu, “Arming oncolytic M1 virus with gasdermin E enhances antitumor efficacy in breast cancer,” iScience, vol. 27, no. 11, 111148, Oct. 2024.
[6] S. G. Ahmed, A. Abdelanabi, M. Doha, and G. J. Brenner, “Schwannoma gene therapy by adeno-associated virus delivery of the pore-forming protein Gasdermin-D,” Cancer Gene Ther., vol. 26, pp. 259–267, 2019.
[7] Y. Lu, W. He, X. Huang, Y. He, X. Gou, X. Liu, Z. Hu, W. Xu, K. Rahman, S. Li, S. Hu, J. Luo, and G. Cao, “Strategies to package recombinant Adeno-Associated Virus expressing the N-terminal gasdermin domain for tumor treatment,” Nat. Commun., vol. 12, 7155, Dec. 2021.
[8] J. Lin, S. Sun, K. Zhao, F. Gao, R. Wang, Q. Li, Y. Zhou, J. Zhang, Y. Li, X. Wang, L. Du, S. Wang, Z. Li, H. Lu, Y. Lan, D. Song, W. Guo, Y. Chen, F. Gao, Y. Zhao, R. Fan, J. Guan, and W. He, “Oncolytic Parapoxvirus induces Gasdermin E-mediated pyroptosis and activates antitumor immunity,” Nat. Commun., vol. 14, 224, Jan. 2023.
[9] J. Lin, F. Liu, F. Gao, Y. Chen, R. Wang, X. Wang, Y. Li, Q. Li, S. Sun, Z. Li, Y. Lan, H. Lu, W. Guo, L. Du, F. Gao, D. Song, K. Zhao, J. Guan, and W. He, “Vesicular stomatitis virus sensitizes immunologically cold tumors to checkpoint blockade by inducing pyroptosis,” Biochim. Biophys. Acta Mol. Basis Dis., vol. 1868, no. 12, 166538, Dec. 2022.
[10] S. Shen, H. Guo, Y. Li, L. Zhang, Y. Tang, H. Li, X. Li, P.- H. Wang, X.-F. Yu, and W. Wei, “SARS-CoV-2 and oncolytic EV-D68-encoded proteases differentially regulate pyroptosis,” J. Virol., vol. 98, no. 2, e0190923, Feb. 2024.
[11] L. Hu, M. Chen, X. Chen, C. Zhao, Z. Fang, H. Wang, and H. Dai, “Chemotherapy-induced pyroptosis is mediated by BAK/BAX-caspase-3-GSDME pathway and inhibited by 2-bromopalmitate,” Cell Death Dis., vol. 11, no. 4, 281, Apr. 2020.
[12] A. Wu, Z. Li, Y. Wang, Y. Chen, J. Peng, M. Zhu, Y. Li, H. Dean&Francis ISSN 2959-409X Song, D. Zhou, C. Zhang, Y. Lv, and Z. Zhao, “Recombinant measles virus vaccine rMV-Hu191 exerts an oncolytic effect on esophageal squamous cell carcinoma via caspase-3/GSDME- mediated pyroptosis,” Cell Death Discov., vol. 9, no. 1, 171, May 2023.
[13] C. Rogers, T. Fernandes-Alnemri, L. Mayes, D. Alnemri, G. Cingolani, and E. S. Alnemri, “Cleavage of DFNA5 by caspase-3 during apoptosis mediates progression to secondary necrotic/pyroptotic cell death,” Nat. Commun., vol. 8, 14128, 2017.
[14] Y. Zhang, T. Xu, H. Tian, J. Wu, X. Yu, L. Zeng, F. Liu, Q. Liu, and X. Huang, “Coxsackievirus Group B3 has oncolytic activity against colon cancer through Gasdermin E-mediated pyroptosis,” Cancers (Basel)., vol. 14, no. 24, 6206, Dec. 2022.
[15] Z. M. Wang, M. K. Li, Q. L. Yang, S. X. Duan, X. Y. Lou, X. Y. Yang, Y. Liu, Y. W. Zhong, Y. Qiao, Z. S. Wang, L. Sun, and F. Qian, “Recombinant human adenovirus type 5 promotes antitumor immunity via inducing pyroptosis in tumor endothelial cells,” Acta Pharmacol. Sin., vol. 45, no. 12, pp. 2646–2656, Dec. 2024.
[16] A. Salmaninejad et al., “PD-1/PD-L1 pathway: basic biology and role in cancer immunotherapy,” J. Cell Physiol., vol. 234, pp. 16824–16837, 2019.
[17] W. Su, W. Qiu, S. J. Li, S. Wang, J. Xie, Q. C. Yang, J. Xu, J. Zhang, Z. Xu, and Z. J. Sun, “A dual-responsive STAT3 inhibitor nanoprodrug combined with oncolytic virus elicits synergistic antitumor immune responses by igniting pyroptosis,” Adv. Mater., vol. 35, no. 11, e2209379, Mar. 2023.
[18] Y. Y. Wang, J. Wang, S. Wang, Q. C. Yang, A. Song, M. J. Zhang, W. D. Wang, Y. T. Liu, J. Zhang, W. M. Wang, Z. Xu, and Z. J. Sun, “Dual-responsive epigenetic inhibitor nanoprodrug combined with oncolytic virus synergistically boost cancer immunotherapy by igniting Gasdermin E-mediated pyroptosis,” ACS Nano, Jul. 2024.
[19] S. M. Man, R. Karki, and T.-D. Kanneganti, “Molecular mechanisms and functions of pyroptosis, inflammatory caspases and inflammasomes in infectious diseases,” Immunol. Rev., vol. 277, pp. 61–75, 2017.
[20] S. L. Longo, C. Griffith, A. Glass, E. J. Shillitoe, and D. E. Post, “Development of an oncolytic herpes simplex virus using a tumor-specific HIF-responsive promoter,” Cancer Gene Ther., vol. 18, pp. 123–134, 2011.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
